# Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

> **NCT03905642** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 49 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Arikayce™

## Key facts

- **NCT ID:** NCT03905642
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-08
- **Primary completion:** 2010-11-02
- **Final completion:** 2010-11-02
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905642, "Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03905642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*